At a glance
ClinicalIndex Comparison Record- ✓Women aged 50-65 years
- ✓Personal or family history of mood disorder
- ✓Hypothyroidism
- ✓Diabetes
- ✕Possible or probable Alzheimer's disease or dementia
- ✕History of cerebrovascular disease
- ✕History of myocardial infarction within the previous year
- ✕History of unstable heart disease
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Cognitive Effects of Memantine in Postmenopausal Women at Risk of Dementia: a Pilot Study
In Brief
A clinical study evaluating Namenda for Dementia. Completed, enrolled 22 participants across 1 site.
Detailed Summary
This research aims to explore the effectiveness of memantine (Namenda) in treating post-menopausal women between the ages of 50 and 65, who are at risk for cognitive decline. Memantine has already been shown to offer cognitive benefits to patients suffering from Alzheimer's disease, but it's potential for treating those at risk for cognitive decline without Alzheimer's disease or other dementia has yet to be evaluated. It is possible that memantine may offer neurocognitive benefits to this population, as well. Participants are asked to take medication for six months, complete neuropsychological testing, and one blood draw.
Study Details
Timeline
Interventions
Namenda has already been shown to offer cognitive benefits to patients suffering from Alzheimer's disease, but it's potential for treating those at risk for cognitive decline without Alzheimer's disease or other dementia has yet to be evaluated. It is possible that memantine may offer neurocognitive benefits to this population, as well. Participants are asked to take medication for six months, complete neuropsychological testing, and one blood draw.